智通财经APP讯，华控康泰(01312)公布，该集团预期2024年取得综合亏损净额约7920万-1.188亿港元，而2023年综合亏损净额约6110万港元。
公告称，综合亏损净额增加主要由于下列原因：集团于2023财政年度就出售附属公司取得一次性收益约1.105亿港元，而2024财政年度并无取得该收益;及该集团确认集团健身业务的特许协议相关无形资产减值约超过1700万港元。该减值主要由于集团于中国台湾的健身业务的复苏较预期缓慢，其未能如集团于新加坡的健身业务一样强劲复苏。
尽管如此，该集团预期2024财政年度的整体收入及毛利较2023财政年度取得增长，乃主要由于下列因素的综合影响：由于对集团核心产品(尤其是同方药业集团有限公司的产品)的需求上升及集团采取更为有效和丰富的营销策略，使得集团医药业务的收入及毛利大幅增加;集团于新加坡的健身业务已自新冠疫情影响中复苏，其收入及毛利增加;及由于在2024财政年度实施了有效成本控制措施，集团的行政费用大幅减少。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.